Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AbbVie Soothes Safety Fears With More Upadacitinib RA Data

Executive Summary

Following the fifth positive pivotal trial for AbbVie's JAK1 inhibitor in rheumatoid arthritis, it is looking increasingly likely that upadacitinib is going to be approved next year, although the company is hoping robust safety data mean that it will not get a black box warning similar to the one issued by the FDA for Lilly's recently approved same-class rival Olumiant.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts